A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis

Vaccine

Volumn 29, Issue 19, 2011, Pages 3531-3537

  Chakravarty, Jaya ^a   Kumar, Subodh ^a   Trivedi, Sonali ^a   Rai, Vijay K ^a   Singh, Anup ^a   Ashman, Jill A ^b   Laughlin, Elsa M ^b   Coler, Rhea N ^b   Kahn, Stuart J ^b   Beckmann, Anna Marie ^b   Cowgill, Karen D ^b   Reed, Steven G ^b   Sundar, Shyam ^a   Piazza, Franco M ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvants; Immunologic; Leishmaniasis; Leishmaniasis vaccines; Visceral

Indexed keywords

IMMUNOLOGICAL ADJUVANT; LEISHMANIA VACCINE; POLYPROTEIN; RECOMBINANT LEISHMANIA POLYPROTEIN LEISH F1 PLUS MPL SE VACCINE; UNCLASSIFIED DRUG;

ADULT; AGGLUTINATION TEST; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INDIAN; LEISHMANIA DONOVANI; MALAISE; MALE; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; VISCERAL LEISHMANIASIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; CYTOKINES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; LEISHMANIA; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LIPID A; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79955028631     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.096     Document Type: Article

References (30)

1. Alvar J., Yactayo S., Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006, 22(December (12)):552-557.
2. Bora D. Epidemiology of visceral leishmaniasis in India. Natl. Med. J. India 1999, 12(March-April (2)):62-68.
3. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Micro Inf Dis 2004, 27(September (5)):305-318.
4. Meheus F., Boelaert M. The burden of visceral leishmaniasis in South Asia. Trop. Med. Int. Health 2010, 15(July (suppl 2)):1-3.
5. Magill A.J., Leishmaniasis Hunter's tropical medicine and emerging tropical diseases 2000, 665-687. WB Saunders Company, Philadelphia. G.T. Strickland (Ed.).
6. Kedzierski L., Sakthianandeswaren A., Curtis J.M., Andrews P.C., Junk P.C., Kedzierska K. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr. Med. Chem. 2009, 16(5):599-614.
7. Meheus F., Boelaert M., Baltussen R., Sundar R. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop. Med. Int. Health 2006, 11(November (11)):1715-1724.
8. Sarnoff R., Desai J., Desjeux P., Mittal A., Topno R., Siddiqui N.A., et al. The economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India. Trop. Med. Int. Health 2010, 15(July (suppl 2)):42-49.
9. Sundar S.S., Arora R., Singh S.P., Boelaert M., Varghese B. Household cost-of-illness of visceral leishmaniasis in Bihar, India. Trop. Med. Int. Health 2010, 15(July (suppl 2)):50-54.
10. Hasker E., Singh S.P., Malaviya P., Singh R.P., Shankar R., Boelaert M., et al. Management of visceral leishmaniasis in rural primary health care services in Bihar, India. Trop. Med. Int. Health 2010, 15(July (suppl 2)):55-62.
11. Webb J.R., Kaufmann D., Campos-Neto A., Reed S.G. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 1996, 157(December (11)):5034-5041.
12. Webb J.R., Campos-Neto A., Ovendale P.J., Martin T.I., Stromberg E.J., Badaro R., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 1998, 66(July (7)):3279-3289.
13. Skeiky Y.A., Coler R.N., Brannon M., Stromberg E., Greeson K., Crane R.T., et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002, 20(September (27-28)):3292-3303.
14. Casella C.R., Mitchell T.C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 2008, 65(October (20)):3231-3240.
15. Persing D.H., Coler R.N., Lacy M.J., Johnson D.A., Baldridge J.R., Hershberg R.M., et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 2002, 10(Suppl 10):S32-S37.
16. Reed S.G., Coler R.N., Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev Vaccines 2003, 2(April (2)):239-252.
17. Coler R.N., Skeiky Y.A., Bernards K., Greeson K., Carter D., Cornellison C.D., et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant. Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 2002, 70(August (8)):4215-4225.
18. Velez I.D., Gilchrist K., Martinez S., Ramirez-Pineda J.R., Ashman J.A., Alves F.P., et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2009, 28(December (2)):329-337. Epub 2009 October 30.
19. Nascimento E., Fernandes D.F., Vieira E.P., Campos-Neto A., Ashman J.A., Alves F.P., et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 2010, 28(September (40)):6581-6587. Epub 2010 August 3.
20. Llanos-Cuentas A., Calderon W, Cruz M., Ashman J.A., Alves F.P., Coler R.N., et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 2010, 28(October (46)):7427-7435. Epub 2010 September 17.
21. Burns J.M., Shreffler W.G., Benson D.R., Ghalib H.W., Badaro R., Reed S.G. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci USA 1993 Jan 15, 90(2):775-779.
22. ICSSC. Monitoring and Reporting Adverse Events: Appendix VII www Resource Links. 2003 [updated February 6, 2003; cited 2009 April 6]; Available from: http://www.icssc.org/Documents/Resources/AEManual2003AppendicesFebruary_06_2003%2520final.pdf.
23. BD Cytometric Bead Array (CBA) Human Th1/Th2 cytokine kit instruction manual 2007, Becton Dickinson and Company.
24. Singh S.P., Picado A., Boelaert M., Gidwani K., Andersen EW, Ostyn B., et al. The epidemiology of Leishmania donovani infection in high transmission foci in India. Trop. Med. Int. Health 2010, 15(July (suppl 2)):12-20.
25. Schenkel K., Rijal S., Koirala S., Koirala S., Vanlerberghe V., Van der Stuyft P., et al. Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors. Trop. Med. Int. Health 2006, 11(December (12)):1792-1799.
26. Gidwani K., Kumar R., Rai M., Sundar S. Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. Am. J. Trop. Med. Hyg. 2009, 80(March (3)):345-346.
27. Bern C., Hightower A.W., Chowdhury R., Ali M., Amann J., Wagatsuma Y., et al. Risk factors for kala-azar in Bangladesh. Emerg. Infect. Dis. 2005, 11(May (5)):655-662.
28. Manson-Bahr P.E. Immunity in kala-azar. Trans. R. Soc. Trop. Med. Hyg. 1961, 55(November):550-555.
29. Khalil E.A., El Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000, 356(November 9241):1565-1569.
30. Hailu A., Musa A.M., Royce C., Wassunna M. Visceral leishmaniasis: new health tools are needed. PLoS Med 2005, 2(July (7)):e211.